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DORES. R. M., H. AKIL AND S. J. WATSON. Strategies.[or studying opioid peptide regulation at the gene, message 
and protein levels. PEPTIDES 5" Suppl I, %17, 1984.--Three opioid peptide precursors have been isolated and charac- 
terized in endocrine and nervous tissue: pro-opiomelanocortin, pro-enkephalin, and pro-dynorphin. Since each of those 
opioid peptide systems have been extensively characterized both biochemically and anatomically, this review will focus on 
strategies for studying the regulation of these systems at the levels of gene transcription, message translation, post- 
translational processing, secretion, and target cell receptor interaction. 
Opioid peptides Transcription Translational Post-translational processing Secretion 
THE endorphins consist of a collection of three biochemi- 
cally discrete families ofopioid peptides which are present as 
distinct systems in the pituitary as well as the central and 
peripheral nervous systems. As a result of the combined use 
of various immunological, biochemical, and molecular 
technologies, the end products of these systems have been 
fully characterized and the structure of the specific mRNAs, 
and in some cases the genes which code for these end prod- 
ucts, have also been characterized. These topics have been 
reviewed extensively [4, 41, 43], however, based on this in- 
formation it is now possible to outline strategies to investi- 
gate the regulatory biology of opioid peptide systems in pitui- 
tary and nervous tissue. This review will focus on current 
approaches for understanding the regulation of these sys- 
tems. 
THE OPIOID PEPTIDE FAMILIES 
At present three distinct precursors have been isolated in 
mammalian endocrine and nervous tissue which contain 
opioid peptides (Fig. 1): pro-opiomelanocortin, the precursor 
for/3-endorphin-, ACTH- and y-MSH-related end products 
[44]; pro-enkephalin, the precursor for methionine- 
enkephalin-related end products and leucine-enkephalin 
[45]; pro-dynorphin, the precursor for dynorphin- and 
c~-neo-endorphin-related end products [26]. In addition to 
containing at least one copy of the opioid core peptide se- 
quence Tyr-Gly-Gly-Phe(Leu, Met), these precursors share 
a number of properties in common. All three precursors are 
similar in size. For example bovine POMC [44] is 264 amino 
acids in size while human pro-enkephalin [45] and porcine 
pro-dynorphin [26] are, respectively, 267 and 256 amino 
acids in size. All three precursors code for multiple end 
products with cleavage usually, but not exclusively, occur- 
ring at pairs of basic residues. Finally, the NH2-terminal re- 
gion of all three precursors is an area rich in cysteine resi- 
dues. In the case of pro-enkephalin and pro-dynorphin the 
placement and number of cysteine residues is nearly identi- 
cal. Collectively these properties underscore the biochemi- 
cal similarities of the three opioid precursor systems and 
raise the possibility that these proteins may have evolved 
from closely allied precursors. 
THE PRO-OPIOMELANOCORTIN SYSTEM 
End products of the pro-opiomelanocortin (POMC) sys- 
tem are synthesized in corticotropic cells of the anterior pi- 
tuitary, melanotropic cells of the intermediate pituitary 
[11,18], distinct neurons in the arcuate nucleus [2], and a 
subset of neurons in the nucleus tractus solitarius [31]. The 
network of POMC neurons in the brain is depicted in Fig. 2. 
Post-translational processing of POMC has been most thor- 
oughly studied in the pituitary of mammals. In the anterior 
pituitary POMC is initially cleaved to yield/3-1ipotropin (/3- 
LPH; the COOH-terminal third of POMC) and ACTH 
biosynthetic intermediate (the NH2-terminal two thirds of 
POMC). The latter form is further cleaved to yield ad- 
renocorticotropin (ACTH) and 16K fragment (the y- 
MSH-containing NH,,-terminal third of POMC) as end prod- 
ucts, while approximately one third of the/3-LPH is further 
cleaved to yield y-LPH (the NH..,-terminal two thirds of 
/3-LPH) and opiate active/3-endorphin (the COOH-terminal 
31 residues of/3-LPH) [18]. By contrast in the intermediate 
pituitary, 16K fragment, ACTH and /3-LPH serve as 
biosynthetic intermediates rather than end products [I 1]. 
16K fragment is cleaved to several lower molecular weight 
forms including y-MSH-related peptides, while essentially 
all the ACTH is cleaved to yield c~-melanotropin (o~-MSH) 
and CLIP (corticotropin-like intermediate lobe peptide) as 
end products. Likewise essentially all the/3-LPH is cleaved 
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FIG. 1. Opioid Peptide Families. Abbreviations: POMC, pro-opiomelanocortin; ACTH, adrenocor- 
ticotropin:/3-LPH, beta lipotropin; T-MSH, gamma-melanocortin; ~-MSH, alpha melanotropin: CLIP, 
corticotropin-like intermediate lobe peptide; T-LPH, gamma lipotropin; B-End-31, beta-endorphin(1- 
31): N-Frag, NH~-terminal fragment of T-LPH: /3-MSH, beta-me[anotropin: /3-END-27, beta- 
endorphin(1-27); Pro-Enk, pro-enkephalin; Syn-E, synenkephalin: ME, [Met]enkepbalin: ME-8, 
[Met]enkepbalin-Arg-Gly-Leu; ME-7, [Met]enkephalin-Arg-Phe, LE, [Leu]enkepbalin; Peptide F. 
Pro-enk(107-140): Peptide E, Pro-enk(210-235): Pro-Dyn, pro-dynorphin: L~-Neo, alpha-neo- 
endorphin; /3-Neo, beta-neo-endorphin: Dyn A-17, dynorphin A(1-17): Dyn A-8, dynorphin A(I-8): 
Leu-M, leu-morphin: Dyn B, pro-dyn(228-240); C, cysteine; K, lysine: R. arginine. The scale is I cm 
equals five amino acids. Modified after Mains et ~U. 158]. 
to yield /3-LPH-related peptides and /3-endorphin-sized 
material as end products. Following the proteolytic cleavage 
of/3-endorphin from /3-LPH, /3-endorphin is further post- 
translationally modified by a combination of COOH-terminal 
proteolytic cleavage and cL N-acetylation to yield opiate in- 
active c~, N-acetyl-/Lendorphin(1-27) and (t, N-acetyl- 
/3-endorphin(1-26) as the major end products [19, 38, 57]. 
Processing of POMC in the arcuate nucleus appears to 
resemble the processing pattern in the intermediate pituitary 
in that the principal end products are c~-MSH-sized and 
/3-endorphin-sized forms [35]. One significant difference be- 
tween these two regions, however,  is that the level of acety- 
lation of  c~-MSH- and/3-endorphin-related material is much 
lower in the arcuate nucleus than in the intermediate pitui- 
tary [20,55]. In the terminal fields of the POMC-arcuate sys- 
tem, the levels of acetylated/3-endorphin-sized material in- 
crease, but never approach the level of acetylation seen in 
the intermediate pituitary 12]. Little is known about the 
processing of POMC in the nucleus tractus solitarius; how- 
ever, analyses of extracts of brainstem indicate that 
/3-endorphin-sized material is primarily COOH-terminally 
truncated and c~, N-acetylated [56]. 
THE P R O - E N K E P H A L I N  SYSTEM 
End products of the pro-enkephalin (pro-enk) precursor 
are found in the adrenal medulla and are distributed widely in 
the central nervous system [41]. Figure 2 contains a list of 
pro-enk cell bodies found in brain. Because of the vast, 
complicated distribution of the pro-enk system in the brain, 
it has been very difficult to establish cell body-terminal field 
relationships. In addition, little progress has been made in 
understanding the steps involved in the post-translational 
processing of pro-enk in either the adrenal medulla or brain. 
What is clear is that this precursor yields four copies of 
[Met]enkephalin, one copy of [Leu]enkephalin and at least 
two [Met]enkephalin extended peptides as end products [25]. 
In addition, a number of studies indicate that larger forms, 
containing more than one enkephalin sequence, may also 
serve as end products [34]. 
THE PRO-DYNORPHIN SYSTEM 
End products of the pro-dynorphin (pro-dyn) system also 
enjoy a wide distribution in the central nervous system, and 
like the pro-enk system, there are several pro-dyn cell body 
regions in the brain (Fig. 2) [30]. Although there are regions 
in the brain where the pro-enk and the pro-dyn systems over- 
lap, anatomical studies using several antisera directed 
against regions of either pro-dyn or pro-enk have demon- 
strated that these two systems are anatomically distinct [53]. 
Furthermore, these studies suggest that pro-dyn is not a 
major source of [Leu]enkephalin in brain. The steps in the 
post-translational processing of pro-dyn have not been de- 
termined, however, the following end products have been 
identified: ~-, and /~-neo-endorphin, dynorphin A(1-17), 
dynorphin A(l-8) ,  leumorphin, and dynorphin B (Fig. 1) [21, 
23, 27, 33, 48]. Recent studies on the ratio of dynorphin 
A(I-17) and dynorphin A(I-8)  in different regions of the 
brain suggest that pro-dyn may undergo differential post- 
translational proteolytic processing [54]. 
POTENTIAL REGULATORY SITES 
Given our present level of understanding of the three 
opioid systems, it appears that pituitary-POMC may be the 
best model for investigating different strategies of regulation. 
In a typical secretory cell, the synthesis and release of a 
polypeptide is via a cascade sequence which begins with 
transcription, proceeds through translation and post- 
translational processing and concludes with secretion. In the 
nucleus, transcription of a specific gene results in the syn- 
thesis of specific hn RNA (heterologous RNA). Studies on 
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FIG. 2. Anatomical distribution of endorphins in the brain. These schematic horizontal drawings show 
the distribution of POMC (panel 1), pro-enkephalin (panel 2) and pro-dynorphin (panel 3) neurons in 
the rat brain. To the right is a list of brain regions where perikarya/fibers of each system are found. 
Each system is designated by its respective number (e.g., 2/2,3:enkephalin perikarya/enkephalin and 
dynorphin fibers). Note also that each line pointing to a specific structure to panel 3 also designates the 
same structure in panels 1 and 2. The larger dynorphin perikarya represent the hypothalamic mag- 
nocellular neurons. 
several eucaryotic gene systems indicate that hnRNA is 
post-transcriptionally processed (i.e., removal of introns, 
proper arrangement of exons, 3' polyadenylation) to yield 
mature mRNA [13]. In the cytoplasm, mRNA containing the 
code for polypeptides destined for secretion are translated 
on the rough endoplasmic reticulum. During translation im- 
portant processing events occur including the insertion of the 
signal peptide region of the nascent polypeptide through the 
bilayer of the endoplasmic reticulum, eventual removal of 
the signal peptide, and co-translational modifications such as 
glycosylation and phosphorylation. Following the termina- 
tion of translation, the newly synthesized polypeptide passes 
through the endoplasmic reticulum and Golgi to the secre- 
tory granule. At this time a series of post-translational events 
may occur including proteolytic cleavage and enzymatic 
modification (i.e., acetylation, amidation and sulfation). Dur- 
ing storage and secretion, the availability of different pools 
of granules for release may represent yet another level of 
regulation. Finally following release, selectivity at the recep- 
tor may provide another area for fine tuning. 
In the following sections each of these potential regula- 
tory sites will be considered using the POMC-pituitary sys- 
tem as a model. Where appropriate, examples will be pre- 
sented for opioid systems in the brain. Finally, studies on 
other peptidergic systems that may serve as models for un- 
derstanding opioid peptide regulation will be cited. Where 
appropriate the value of multiple strategies will be empha- 
sized. 
Transcription 
Stimuli which either positively or negatively affect tran- 
scription will ultimately influence the amount of precursor 
synthesized. A paradigm which has been used on the 
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POMC-anterior pituitary system to measure changes in tran- 
scription is adrenalectomy. The hypothalamus-anterior 
pituitary-adrenal axis maintains the steady state levels of 
glucocorticoids in plasma. Removal of the adrenals results in 
a rapid decline in plasma glucocorticoids which is accom- 
panied by an increase in the secretion and synthesis of 
POMC end products in corticotrophs. Two approaches 
which have been used to measure changes in transcription in 
this paradigm are: (1) measurement of de  m~vo synthesis of 
hn RNA; (2) changes in the level of POMC mRNA. 
The de  n o v o  synthesis of hnRNA in anterior pituitary has 
been measured by the in vi tro nuclear transcription assay [9] 
and POMC-specific complementary DNA (cDNA) probes. 
In this procedure nuclei, isolated from anterior pituitary cells 
following adrenalectomy, are incubated in medium contain- 
ing radiolabeled nucleotides and the level of total 
radiolabeled hnRNA is measured by scintillation counting 
and compared to POMC specific hnRNA. Using this proce- 
dure a several fold increase in POMC hnRNA was observed 
in nuclei isolated from adrenalectomized animals as com- 
pared to control animals [9]. Beyond a simple increase in 
POMC hnRNA synthesis, it is not apparent whether ad- 
renalectomy has any effect on the rate or nature of post- 
transcriptional processing of POMC hn RNA. This point is 
particularly relevant since studies on the synthesis of cal- 
citonin mRNA indicate that post-transcriptional processing, 
that is the rearrangement of exons in the final mRNA tran- 
script, can change as a function of  the time in culture [7]. 
Thus the importance of the information gained from nuclear 
transcription assays is considerably enhanced when taken in 
conjunction with assays that quantify the amount of mature 
mRNA in a cell. This approach has been used for the anterior 
pituitary/adrenalectomy paradigm. Birnberg et a/. [9] not 
only measured nuclear transcription rates in the anterior pi- 
tuitary, but also quantified changes in the levels of POMC 
mRNA as a result of adrenalectomy by solution hybridiza- 
tion to a POMC-specific cDNA probe. This procedure 
demonstrated a 15-20 fold increase in POMC mRNA in 
anterior pituitary 18 days after adrenalectomy. Thus taken 
together these two procedures indicate that adrenalectomy 
induces an increase in POMC mRNA synthesis in cortico- 
trophs. 
Quantitation of mRNA levels with specific complemen- 
tary DNA probes has also been applied to other opioid sys- 
tems as well. For  example, the POMC-intermediate pituitary 
system is regulated by tonic inhibition via a dopaminergic 
pathway [10]. Daily intraperitoneal injections of the 
dopamine antagonist haloperidol results in an increase in the 
release and synthesis of POMC end products in melano- 
trophs. Chen et al. [ 10] have observed a 3 to 5 fold increase in 
POMC mRNA levels in the intermediate pituitary, as meas- 
ured by hybridization to a specific POMC complimentary 
DNA on nitrocellulose filters (Dot Blot Procedure), as a re- 
sult of haloperidol treatment. Extending these approaches to 
brain, Tang et  al. [50] have observed a four fold increase in 
pro-enk mRNA levels, as measured by solution hybridiza- 
tion, accompanied by a two fold increase in [Met]enkephalin 
levels in the striatum following haloperidol treatment. The 
success of these experiments indicate that the hybridization 
procedures for measuring mRNA will be useful in monitoring 
the regulation of transcription in other brain regions. 
7) 'ans la t ion  
The procedures outlined in the preceding section provide 
information on changes in the level of mRNA transcript, but 
do not indicate whether elevated levels of mRNA transcript 
necessarily result in increased synthesis of translation prod- 
ucts (i.e., POMC, Pro-enk, Pro-dyn). In this section, exam- 
ples will be presented to show that changes in the rate of 
translation or in the rate of co-translational processing are 
useful indicators of the activity of a cell. 
In the case of pituitary tissue, quantitation of newly syn- 
thesized translation product can be done via an in vitro pulse 
radiolabeling paradigm. Pituitary tissue is well suited for this 
sort of analysis since either enzymatically dispersed pituitary 
cell suspensions or monolayer cultures of enzymatically dis- 
persed pituitary cells are viable in culture for extended 
periods [39,42]. Utilizing this approach, Shiomi and Akil [49] 
have assessed the effect of acute stress on the rate of syn- 
thesis of POMC. Since acute stress is known to induce the 
coordinate release of ACTH and /~-endorphin from the 
anterior pituitary, the question was asked whether this 
paradigm had any effect on the rate of synthesis and post- 
translational processing of POMC. Pulse labeling of anterior 
pituitary cells obtained from rats following acute stress re- 
vealed a 128% increase in immunoprecipitable POMC-sized 
material as determined by SDS PAGE analysis. Further- 
more, pulse/chase studies indicated a significant decrease in 
the half life of POMC from 35 min in control animals to 18 
rain in treated animals following acute stress. Thus the acute 
stress paradigm not only affects the level of synthesis of 
POMC in the anterior pituitary, but also the rate of post- 
translational processing. 
Changes in the kinetics of a cell may also be reflected by 
changes in the rate of co-translational processing. While the 
cleavage of signal or leader sequence is co-translational, it 
has a measurable half-life in the case of POMC, on the order 
of a few minutes (Akil e t a / . ,  unpublished data). It is there- 
fore theoretically possible to measure the pre-prohormone 
(i.e., POMC with signal sequence attached), even though it 
constitutes a very small proportion of total POMC. We have 
developed and validated an antiserum specific to POMC- 
signal sequence [3]. Using this antiserum, we have shown 
that during periods of enhanced release and biosynthesis, 
there is a relative increase in immunoreactive pre-POMC. 
For example,  following acute stress which results in 25% 
depletion of pituitary /3-endorphin and ACTH, there is a 
period of increased biosynthesis as indicated by the pulse 
chase study described above, and by the restoration of total 
ACTH//3-endorphin content in the lobe two hours post- 
stress. During those two hours, the amount of measurable 
pre-POMC, and its ratios to total/3-endorphin is significantly 
increased (Akil e t a / . ,  in preparation). 
This approach can also be used to measure specifically 
the rate of conversion of pre-prohormone to prohormone 
using pulse labeling paradigms in primary pituitary cultures 
and specific immunoaffinity columns built with anti-POMC 
signal and anti-/~-endorphin antisera. Here again, activation 
of release (haloperidol-induced in the intermediate lobe) also 
leads to increased incorporation into pre-POMC (increased 
signal immunoreactivity at the end of the pulse period rela- 
tive to control cultures) and increased rate of conversion 
from the pre-pro to the pro forms (Akil e ta / . ,  in preparation). 
It therefore appears that both translational and co- 
translational events can be controlled by changes in demand: 
in this case changes in release and content of POMC prod- 
ucts. 
Both of the procedures outlined above have relied, at 
least in part, on in vi tro radiolabeling procedures as a method 
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for identifying newly synthesized precursor protein. While 
this approach is very applicable for pituitary tissue, culturing 
of dispersed neurons is a far more difficult task. To begin 
with, adult CNS neurons are particularly difficult to maintain 
in culture. Although fetal and neonatal CNS tissue have 
greater viability in culture, studies in several laboratories, 
including our own [5,32], indicate that processing of POMC 
in fetal and neonatal pituitary differs from POMC processing 
in adult tissue. Similar developmental differences may also 
apply to neuronal opioid peptide systems. Based on these 
observations, it may be more appropriate to attempt in vivo 
labeling of brain tissue. This approach has been successfully 
used to elaborate the biosynthesis of  oxytocin and vaso- 
pressin in the magnocellular-posterior pituitary system [47]. 
Although in vivo labeling will be more difficult for the opioid 
peptide systems due to the low density of opioid peptide 
neurons, this procedure may be the best approach for study- 
ing the kinetics of  opioid peptide biosynthesis in the brain. 
However, for the present, a considerable amount of infor- 
mation can be inferred about the biosynthesis of opioid pep- 
tides from biochemical characterization of the steady state 
products of these systems. In particular variations in the 
multiple molecular weight forms of these products can serve 
as indicators of differential regulation. 
Post-l) 'anslatiomd Processing 
Following translation, precursors of low molecular weight 
polypeptides undergo a series of post-translational modifica- 
tions which include proteolytic cleavage of the precursor and 
biosynthetic intermediates, and enzymatic modification of  
the end products. Knowledge of the steps in the biosynthetic 
pathway coupled with complete characterization of the end 
products not only provides information on the function of the 
secretory cell, but also may indicate potential regulatory 
sites in the system. 
In the POMC-pituitary system, differences in proteolytic 
processing of POMC in anterior and intermediate pituitary 
are clearly reflected in the differential biological activities of 
the end products of these regions [4,5]. ACTH is one of the 
major end products of the anterior pituitary and accordingly 
corticotropic cells regulate glucocorticoid synthesis and re- 
lease in the adrenal cortex [8]. By contrast, in the inter- 
mediate pituitary, ACTH is cleaved to a-MSH and CLIP. 
While a-MSH has little, if any, effect on adrenal function in 
adults, this polypeptide is a potent stimulator of physiolog- 
ical color change in several species of non-mammalian ver- 
tebrates 18]. In a similar manner, the proteolytic processing 
of/3-LPH in the pituitary of  mammals is also region specific. 
In the anterior pituitary the end products are roughly equal 
amounts of/3-LPH, T-LPH, and opiate active/3-endorphin 
[18], while in the intermediate pituitary the end products are 
y-LPH-related forms and opiate inactive forms of 
/3-endorphin [11]. Although the function of/3-LPH-related 
end products in the periphery is still unclear, it is intriguing 
to propose that differences in/3-LPH post-translational proc- 
essing, like ACTH post-translational processing, are also 
related to the distinct functions of corticotrophs and 
melanotrophs. Furthermore, shifts in processing patterns in 
a specific region may also be related to differences in func- 
tion. For example, while the molar ratio of  /3-LPH to 
/3-endoprhin in the mouse anterior pituitary is 2:1 [24], 
analysis of extracts of the anterior pituitary of the rhesus 
monkey (Akil et al., unpublished data) reveal a molar ratio of 
/3-LPH to /3-endorphin of 1:2. Differences in the degree of 
post-translational processing of B-LPH are even more 
pronounced as one moves down the phylogenetic tree. In the 
anterior pituitary of the reptile, Am~lis carolinensis, the 
molar ratio of/3-LPH to/3-endorphin is 1:40 and resembles 
the ratio seen in the intermediate pituitary of this species and 
the intermediate pituitaries of mammals [16]. These changes 
in proteolytic processing may indicate that the corticotrophs 
have species specific functions. 
Evidence of differential proteolytic post-translational 
processing is also seen in the pro-dyn system. Weber et a/. 
[54] have reported that the molar ratio of dynorphin(1-17) to 
dynorphin(1-8) varies in different regions of the brain. In 
support of these observations, we have looked at just two 
terminal field regions in the pro-dyn system, the posterior 
pituitary and the substantia nigra, and found that the molar 
ratio of dynorphin(l-17) to dynorphin(l-8) in the former 
terminal field is 1:2 while in the latter terminal field the ratio 
is 1:35 ]17]. 
In addition to examples of differential proteolytic process- 
ing, there are also examples of  differential enzymatic modifi- 
cation of end products in the POMC-pituitary system. For 
example, although both the anterior and intermediate pitui- 
tary of  the rat synthesize /3-endorphin-size material [9[, 
anterior pituitary/3-endorphin is opiate active, while approx- 
imately 90% of the /3-endorphin-sized material in the inter- 
mediate pituitary is o~, N-acetylated [19, 39, 57] and hence 
lacks opiate activity [I]. Accordingly, approximately 90% of 
the o~-MSH-sized material in the rat intermediate pituitary is 
~, N-acetylated, however, in the case of ~-MSH, ~, 
N-acetylation increases the potency of  this polypeptide in 
physiological color change bioassay systems [46]. The de- 
tailed steps in the biosynthetic pathway for the acetylation of 
/3-endorphin- and o~-MSH-sized peptides in the rat inter- 
mediate pituitary are presented in Fig. 3. Based on this 
pathway, it has been proposed that acetylation may serve as 
a mechanism for selectively activating one end product while 
inactivating another end product [55]. While this strategy 
appears appropriate for describing the activities of end prod- 
ucts in the rat intermediate pituitary, a review across species 
indicates that other cellular strategies occur (Table 1). For 
example, in the salmon pituitary all the ,8-endorphin is o~, 
N-acetylated: however, the major form of ~-MSH-sized 
material is ACTH(I-13)NH~ [28,29]. Furthermore, in the 
reptile intermediate pituitary only non-acetylated forms of 
/3-endorphin are synthesized [15]. These observations indi- 
cate that one level of regulation resides in the substrate 
specificity of the post-translational processing enzymes. Yet 
substrate specificity may represent just one level of control. 
There is increasing evidence that in the intermediate pitui- 
tary of the toad, Xenopus laevis, the acetylation ot 
ACTH(I-  13)NH._, to o~-MSH (o~, N-acetyl [ACTH(1-13)NH,] 
occurs at secretion [40]. Thus, in this system the enzymatic 
modification of ACTH(I-13)NH2 is directly tied to physi- 
ological demand. These examples point out that the synthe- 
sis and activation of the post-translational processing 
enzymes represents yet another set of  strategies used by the 
peptidergic cell for regulating its functional capabilities. 
Secr~'tiOll 
Since it is now apparent that any given precursor can 
yield multiple products which vary in specificity and biologi- 
cal activity, it becomes critical to determine which products 
are released, and under which circumstances. In some in- 
stances the complexities of the processing and the post- 
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TABLE 1 
ACEYLATION OF f3-ENDORPHIN AND ~MSH 
Species Tissue ~-Endorphin ~MSH References 
Rat Intermediate Pituitary 9092 Acetylated 9092 Acetylated 119, 20, 21, 
35, 571 
Salmon* Pituitary All Acetylated Major Form: ACTH( 1-13)NH_, 128,29] 
Rep t i l e+  Intermediate Pituitary All Non-Acetylated Not Determined [17] 
Amphibian:i: Intermediate Pituitary Not Determined Acetylation of ACTH( 1-13)N H, [40] 
Occurs at Secretion 
*()ncorhynchus kcm. 
lAmdis carolim, n,sis. 
SXem~pu,~ laevi.~. 
translational modifications are such that it is difficult to de- 
termine which is the main product. For example, in the case 
of the neuro-intermediate lobe, should we conceive of the 
opioid active/3-endorphin(1-31) as the main product, with 
the N-acetylated forms as metabolites? Or is the last pep- 
tide generated by the pathway, e.g., c~, N-acetyl- 
/3-endorphin(1-26), the one which is differentially re- 
leased? Is it conceivable that under different conditions of 
demand, the system would utilize different peptides with dif- 
ferent potencies or dissimilar physiological effects? These 
are obviously questions which are key to our understanding 
the physiology of the system and its regulation. Unfortu- 
nately, there is little hard evidence on this subject and a good 
number of preconceptions. For example, it is easy to assume 
that "more pharmacologically potent is better," which 
would lead us to construe /3-endorphin(1-27) or 
~-endorphin(l-26) as metabolites. However, one can cer- 
tainly conceive of conditions where the release of an ex- 
tremely potent or long acting opioid at a given synapse is not 
necessary or even desirable, and where the delivery of a less 
extreme message is ideal. Alternatively, in conditions of high 
demand, the longer acting, more potent agent may be re- 
quired. It is also easy to think primarily in terms of one main 
function, e.g., activity of the opioid peptides at the opioid 
receptors, which would lead us to the conception that the 
N-acetylated forms are totally inactive. However, it is now 
well known that peptides carry more than one message of 
biological activity, and several non-opioid effects of the 
opioid peptides have indeed been demonstrated [14,52J. 
Given that we have no a priori way of determining the 
pattern of release or its biological regulation, we need to 
develop models for studying these questions. The use of 
potassium-stimulated release is fraught with difficulties, 
since this method does not discriminate between various re- 
leasable pools. What is required is the systematic study of 
multiple forms released under well-defined conditions of 
high or low demand in order to understand the activation of a 
particular system. These conditions can be induced phar- 
macologically or physiologically by altering the animal's en- 
vironment. An example of a viable pharmacological model is 
the activation of release from adrenal medulla via cholinergic 
agents [46,51]. This model has been useful in demonstrating 
that the enkephalins are co-released with the catechola- 
mines, and that several opioid peptides are liberated. These 
include [Met]- and [Leu]enkephalin, [Met]-enkephalin- 
Arg-Gly-Leu and lMet]-enkephalin-Arg-Phe. However, the 
releasability of these compounds relative to the longer more 
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FIG. 3. Schematic of the acetylation of/3-endorphin and ~,-MSH in 
rat intermediate pituitary. The wide arrows indicate major 
biosynthetic pathways, whereas the narrow arrows indicate minor 
pathways. The steps in the biosynthetic pathway between 
/3-endorphin(1-26) and y-endorphin, and the steps in the pathway 
between ACTH and ACTH( 1-13)NHe are not known and these parts 
of the respective biosynthetic pathways are represented by two ar- 
rows in succession. See Mains ~,t a/. 1581. 
stable pro-enkephalin products, such as peptides E or F, has 
not been systematically examined. 
Even the better studied POMC system has not been well 
investigated with regard to differential release of multiple 
forms. Herbert and his co-workers [6] have used an anterior 
lobe primary culture model system, and shown that a 
medium containing endogenous releasing factor(s) differen- 
tially liberates the smaller, more completely processed 
POMC products, such as/3-endorphin, rather than the pre- 
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cursors or biosynthetic intermediates. In our own labora- 
tory, we have been addressing this issue by studying the 
effect of stress on release of multiple forms of/3-endorphin 
from the neuro-intermediate lobe and from the midbrain of  
the rat (Akil et al.. in preparation). Our results to date 
suggest that, in this model, the most processed forms are 
released preferentially. This means that, in the case of mid- 
brain,/3-endorphin(1-27) or/3-endorphin(1-26) are released 
in preference to the ten-fold more potent/3-endorphin( 1-31). 
When the brain POMC system is challenged, then allowed to 
recover over 24 hours, the shorter forms accumulate, and are 
released again upon further stress. This does not mean that 
/3-endorphin(l-31) is not released at all or that the shorter 
forms are exclusively liberated. It simply means that the 
ratios of forms seen in terms of  content do not predict the 
ratios of  released peptides. This might suggest that the most 
modified, last product of the biosynthetic pathway is, in- 
deed, the "'true product" of the system. However,  this is a 
hasty conclusion. We still do not know what happens when 
the demand on the system is sustained and little time is avail- 
able for full recovery and complete processing. It is conceiv- 
able that the POMC system in brain liberates the less potent 
material as a matter of course,  but that continued demand on 
the system would lead to the exocytosis of the pool which 
contains the more opiate-active/3-endorphin(1-31). This may 
impart a great deal of flexibility to the system, allowing it to 
respond to various levels of demand by delivering opioids of  
varying and appropriate potencies. Such a hypothesis re- 
quires systematic testing under a number of physiological 
and pharmacological challenges, and with different time 
courses of recovery. It does, however, illustrate the possible 
richness of these multi-product systems, and the com- 
plexities in their regulation. 
The regulation of release of endogenous opioids may in- 
volve another level of control, beyond the issue of different 
releasable pools. It appears that the overall "re leasabi l i ty"  
of these peptides could be altered by physiological or en- 
vironmental events. A series of experiments was conducted 
in our laboratory concerning possible alterations of releasa- 
bility of POMC products from anterior lobes of rats which 
had undergone various treatments (Young et al.. in prepara- 
tion). Primary culture of the anterior lobes of rats which had 
been subjected to acute stress, repeated daily stress, or no 
stress, were compared in terms of  releasability of 
/3-endorphin and ACTH by the secretagogues CRF and vas- 
opressin. These studies suggested that the repeated activa- 
tion of  the anterior lobe corticotrophs with 25 minutes of  
daily stress (intermittent footshock) for two weeks, leads to 
enhanced releasability of POMC products. The animals with 
a history of repeated daily stress exhibited greater propor- 
tional release of/3-endorphin and ACTH to a given dose of 
CRF, vasopressin or their combination. Furthermore, CRF- 
induced release in these animals was less inhibited by the 
presence of corticosteroids. 
It therefore appears that the POMC system can be regu- 
lated both in terms of which products are released, and the 
ease with which the release does take place. The exact 
mechanisms of these controls remain to be elucidated. It is 
apparent,  however,  that the plasticity of these systems is 
remarkable, and that this level of  control and regulation may 
be critical for integrated function. We are clearly in need of  
understanding the principles of  such regulation, and deter- 
mining whether these principles are unique to a given system 
(e.g., endocrine versus neuronal, POMC versus pro- 
enkephalin), or whether they have a wide heuristic value. 
Re('eptors 
Throughout the above discussion, we have focused on the 
issues concerning control of  peptide biogenesis and release, 
but have said nothing of  receptors. This is clearly only one 
side of the equation. The receiving end of  these systems, be 
it postsynaptic receptors, or endocrine target organs, can 
exhibit a great deal of selectivity and propensity for regula- 
tory controls. A complete discussion of  the issues of recep- 
tor types and regulation is beyond the scope of this paper. 
We shall briefly outline the general features of opioid recep- 
tors and point to the major theoretical questions in this area. 
The multiplicity of  endogenous opioid peptides is 
matched by a multiplicity of opioid receptors. The three re- 
ceptor types which have been best described are the mu 
receptor, which interacts with morphine-like substances, the 
delta receptor which is selective for enkephalin-like sub- 
stances, and the kappa receptor, which is selective for al- 
kaloids of  the type of ketocyclazocine, and for dynorphin 
and neo-endorphin. It is thought that the activation of a par- 
ticular receptor subtype may result in a unique pharmacolog- 
ical profile. Indeed, careful pharmacological charac- 
terizations, both i ,  vivo and i ,  vitro, first led Martin and 
coworkers and Kosterlitz and coworkers 122,37] to put forth 
the concept of multiple receptor types. There are a few dis- 
tinctive characteristics of the activations of specific opioid 
receptors, such as the production of analgesia when mu re- 
ceptors in relevant circuits are activated. However,  the spe- 
cific physiological roles of each receptor subtype are far 
from clear. Furthermore,  the relationship between a particu- 
lar family of opioids and a particular opioid receptor type is 
not well established. There is a tendency to associate the 
delta receptor with the pro-enkephalin family, and the kappa 
receptor with the pro-dynorphin family, based on the prefer- 
ence of the peptide products for these receptor subtypes. 
However,  each precursor produces multiple products with a 
range of selectivity. For example, while [Leu]enkephalin is 
clearly delta selective, [Met]enkephalin is less so, and other 
products of pro-enkephalin can be reasonably potent at the 
mu receptor. Similarly, the pro-dynorphin products, while 
clearly kappa selective, also exhibit a range of specificities. 
Further, /3-endorphin, which derives from the third opioid 
cannot be construed as the endogenous mu ligand. Rather, it 
appears almost equipotent at the mu and delta sites, and has 
been postulated to have its own binding site (Epsilon). In 
other words, there is no obvious opioid family associated 
with the best characterized opioid receptor, the mu sites. 
Instead, autoradiographic studies, when coupled with im- 
munohistochemistry,  reveal the association of mu receptors 
with all three endogenous opioid families [36], Thus, each 
family appears to produce multiple opioid products, capable 
of interacting with multiple opioid receptors, and more than 
one receptor type appears present in the vicinity of the ter- 
minals. The fine local circuitry may be more specialized, and 
may yield selectivity which is hard for us to discern with 
current techniques. However,  it is evident at this stage that a 
simplistic model of one opioid-family: one opioid receptor 
type can not be upheld. Finally, the relations between 
opioids as hormones in the periphery and any specific recep- 
tor type is totally obscure, since there are few well charac- 
terized peripheral opioid endocrine functions, in spite of the 
abundance of opioid peptides in endocrine glands. 
Most likely, the multiple opioid receptors are subject to a 
dizzying number of regulatory processes,  ranging from con- 
trol of their affinity, to their relative numbers, their coupling 
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to second  m e s s e n g e r  sys t ems ,  the i r  poss ib le  in te rac t ions  
amongs t  e ach  o the r ,  or  wi th  o t h e r  m e m b r a n e  c o m p o n e n t s .  
We  should  also bea r  in mind  tha t  e ach  pept ide  can  car ry  
mult iple  messages ,  including non-op io id  ones  J52], and  that  
the opioids  are co- re leased  wi th  o t h e r  po ten t  pep t ides  such 
as A C T H ,  with which  they  may  in terac t  [4]. It is the re fo re  
a p p a r e n t  tha t  a great  deal of  the  b u r d e n  of  cont ro l  lies not  
only  in the  re leas ing  end,  but  in the rece iv ing  end.  The  fine 
tuning  of  the sys tem is likely to resul t  f rom the in ter face  of  
these  two  main  c o m p o n e n t s ,  and the  possibi l i ty of  f eedback  
b e t w e e n  them.  
In conc lus ion ,  it is becoming  c lear  tha t  one can s tudy the  
b io syn the t i c  and  re lease  ac t ions  of  neu ropep t ide  p roduc ing  
cells at a var ie ty  of  levels.  R a t h e r  t han  conc lude  that  there  is 
one  key " r a t e  con t ro l l i ng"  step which  will reflect  the  act ivi ty 
of  the sys tem,  we are more  impre s sed  with changes  unde r  
d e m a n d  t h r o u g h o u t  the  b iosyn the t i c  chain.  In o the r  words ,  
each  level f rom the gene th rough  p recu r so r  syn thes i s  to re- 
lease is s ignif icant ly inf luenced by demand .  The  task for  the 
fu ture  is the  d e v e l o p m e n t  of new tools  for s tudying 
neuropep t ide  t u r n o v e r  and the  careful  appl ica t ion of  these 
classical  cell biological  tools to the neuron .  
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